UNITED STATES OF AMERICA FEDERAL TRADE COMMISSION OFFICE OF ADMINISTRATIVE LAW JUDGES

In the Matter of)
Altria Group, Inc., a corporation,))) Docket No. 9393
and)
JUUL Labs, Inc. a corporation,)))
Respondents.)

ORDER GRANTING NON-PARTY PHILLIP MORRIS INTERNATIONAL INC.'S SECOND MOTION FOR *IN CAMERA* TREATMENT

By Order issued May 26, 2021, the first motion for *in camera* treatment filed by non-party Phillip Morris International Inc. ("PMI") was granted in part and denied without prejudice in part ("May 26 Order"). Pursuant to that Order, PMI filed a second motion for *in camera* treatment for materials that the parties have listed on their exhibit lists as materials that might be introduced at trial in this matter. No party opposes the motion. For the reasons set forth below, PMI's motion is GRANTED.

The standards by which PMI's motion is evaluated are set forth in the May 26 Order. PMI seeks *in camera* treatment for portions of the deposition transcript of Martin King (PX7020/RX0111). PMI supports its motion with a declaration from an assistant general counsel. The declaration provides additional details about the information PMI seeks to protect and explains how the information meets the *in camera* treatment standards. PMI has narrowed the designated page and line numbers it seeks to shield. Accordingly, *in camera* treatment, for a period of five years, to expire June 1, 2026, is GRANTED for the following portions of PX7020/RX0111: 20:19-21; 25:9-12; 33:14-25; 34:2-3; 34:6-17; 34:24-25; 35:2-3; 35:5-6; 35:9-15; 35:22-23; 36:2-5; 36:9-12; 37:24-25; 38:2-5; 38:14-17; 45:9-15; 47:4-11; 51:21-25; 52:2-4; 52:10-24; 53:12-20; 56:19-25; 57:2-6; 57:8-25; 58:4-10; 58:13-15; 58:17-25; 59:2-6; 59:8-11; 59:19-25; 60:2-25; 61:2-9; 61:11-24; 62:4-7; 62:10-16; 63:3-5; 63:10-17; 63:20-21; 65:18-20; 65:22-25; 66:2-8; 66:13-16; 66:18-25; 67:2-8; 67:12-16; 67:18-19; 67:21-23; 68:2-8; 68:24-25; 69:2-10; 70:12-15; 70:23-25; 71:2-7; 72:3-13; 76:22-25; 77:2; 79:21-23; 80:6-9; 80:17-18; 81:6-22; 82:3-25; 83:2-25; 84:2-4; 84:8-17; 84:19-24; 85:3-11; 85:14-16; 89:20-25; 90:11-12; 91:13; 91:20; 92:24-25; 93:2-10; 93:24-25; 94:2-3; 97:9-12; 100:8-20; 105:6-10;

106:3-5; 106:23-24; 107:10-11; 109:19-21; 110:3-5; 110:9-19; 110:22-25; 111:2-6; 112:5-25; 113:2-5; 116:6-20; 117:3-10; 117:18-20; 118:4-24; 120:25; 121:2-8; 121:11-16; 122:7-13; 123:2; 123:15-25; 124:2-5; 124:10-11; 124:19-25; 125:2-8; 125:13-23; 126:2-13; 126:15-22; 130:10-15; 130:17-25; 131:2-11; 131:13-21; 132:6-9; 132:16-19; 132:21-25; 133:4-5; 133:12-25; 134:2-9; 134:11-25; 135:2; 137:22-25; 166:11-15; 172:25; 173:2-20; 174:14-16; 179:10-14; 180:20-25; 181:2-18; 183:14; 186:12-15; 186:18-21; 186:23-25; 189:9-13; 189:24-25; 190:2-5; 190:10-17; 197:23-25; 198:2-4; 201:11-17; 201:19-23; 202:5-7; 202:18-25; 203:2-3; 203:6-19; 210:17-20; 210:23-25; 216: 25; 217:2-7; 220:16-22; 223:2-8; 229:3-5; 231:8-25; 232:2-19; 232:21-22; 232:24-25; 233:2-3; 233:6-12; 233:14-25; 234:2-22; 235:19-20; 235:22-25; 236:2-5; 236:8-25; 237:2-3; 237:10-17; 237:19-25; 238:2-18; 238:20-25; 239:2-3; 239:5-25; 240:2-12; 240:17-25; 241:2-3; 242:8-12; 243:17-24; 248:23-25; 249:2-9; 249:11-25; 250:2; and 251:10-16.

In addition, permanent *in camera* treatment is GRANTED for the sensitive personal information (five personal email addresses) contained in two PMI documents. The sensitive personal information shall be redacted by the parties from PX3028 (at PMI-FTC-000000517) and PX3029 (at PMI-FTC-000000523).

ORDERED:

D. Michael Chappell
Chief Administrative Law Judge

Date: June 7, 2021